ORLANDO — In this video from the American Academy of Ophthalmology meeting, Jennifer I. Lim, MD, MBA, discusses drugs in the pipeline that will provide more durability in retina.
Lim, of the University of Illinois Chicago, highlighted zifibancimig (Genentech), a molecule being studied in the BURGUNDY study, and tyrosine kinase inhibitors Duravyu (vorolanib, EyePoint Pharmaceuticals) and Axpaxli (axitinib, Ocular Therapeutix).